Correlation between frequency of hospitalization of patients with severe copd and severity indices
More details
Hide details
University of Athens Medical School, 2nd Respiratory Medicine Dept
Clinical Research Unit, Athens Army General Hospital
Department of Pneumonology, Veterans’ Hospital of Athens
Pneumon 2011;24(2):164–171
Several parameters have been proposed as risk factors for hospitalization of patients with chronic obstructive pulmonary disease (COPD).

The aim of this study was to investigate the association between changes in parameters expressing various different aspects of disease severity and the frequency of hospitalization of patients with severe COPD without co-morbidities.

Population and Methods:
Of 117 patients with severe COPD recruited for prospective study, 74 completed 2-year monitoring and were classified into 2 groups according to their frequency of hospitalization: Group A (n=39) ≤2 hospitalizations/year, Group B >2 hospitalizations/year (n=35). Parameters measured at baseline and 2 years included: FEV1 % pred, FEV1/FVC ratio, ratio of inspiratory capacity (IC) to total lung capacity (TLC)(IC/TLC), body mass index (BMI), fat free mass index (FFMI), 6 minute walk distance (6MWD), the Borg dyspnoea scale before and after 6MWD, dyspnoea according to the Medical Research Council (MRC) scale, pH and 8-isoprostane in exhaled breath condensate (EBC), serum levels of C-reactive protein (CRP) and fibrinogen, arterial blood gases, the BMI, airflow obstruction, dyspnoea, and exercise capacity (BODE) index and quality of life.

The patients with more frequent hospitalizations showed greater change in the baseline study variables after 2 years. The specific differences were loss of muscle mass, deterioration of airway obstruction, decrease in exercise capacity, increase in airways and systemic inflammation and impairment in quality of life. The most significant changes found to be associated with hospitalization frequency using a regression model were in CRP, 6MWD, fibrinogen, 8-isoprostane and BODE.

In this selected cohort of patients with severe COPD, increased hospitalization frequency was associated with changes in parameters expressing deterioration in exercise capacity and in systemic and airways inflammation.

Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnoea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005– 1012.
Vestbo J, Prescott E, Almdal T, et al. Body Mass, Fat-Free Body Mass, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease from a Random Population Sample. Am J Respir Crit Care Med 2006;173:79-83.
Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004;23:28-33.
Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-255.
Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-796.
Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:418-1422.
Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704.
Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-120.
Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931.
Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004.
Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224-1238.
Cao Z, Ong KC, Eng P, Tan WC, Ng TP. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006;11:188-195.
Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest 2005;128:3810-3816.
Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM; Estudi del Factors de Risc d’Agudització de la MPOC investigators. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003;58:100- 105.
Garcia-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J, Antó JM. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000;16:1037-1042.
Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States,1979 to 2001. Chest 2005;128:2005-2011.
Bakakos P, Κostikas Κ, Loukides S. COPD and Comorbidities Pneumon 2010;23:21-27.
Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591-597.
Marin J, Carrizo S, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory Capacity, Dynamic Hyperinflation, Breathlessness, and Exercise Performance during the 6-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001;163:1395-1399.
Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 1985;41:810-817.
Fletcher CM. Standardized questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ 1960;2:1665.
American Thoracic Society. ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002;166:111- 117.
Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381.
Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773-778.
Clauss, A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957;17:237-246.
Kostikas K, Papatheodorou G, Ganas K, Psathakis K, Panagou P, Loukides S. pH in Expired Breath Condensate of Patients with Inflammatory Airway diseases. Am J Respir Crit Care Med 2002;165:1364–1370.
Loukides S. Expired breath condensate: A new, non-invasive method for the evaluation of airway inflammation. Pneumon 2004;17:39-44.
Kostikas K, Loukides S. Expired breath condensate: A new, noninvasive method for the evaluation. Pneumon 2001;14:184-196.
Psathakis K, Papatheodorou G, Plataki M, et al. 8-Isoprostane, a marker of oxidative stress, is increased in the expired breath condensate of patients with pulmonary sarcoidosis. Chest 2004;125:1005-1011.
Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 Suppl 2):398S-401S.
Schols AM, Fredix EW, Soeters PB, Westerterp KR, Wouters EF. Resting energy expenditure in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 1991;54:983-987.
Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:26- 33.
Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-360.
Parker CM, Voduc N, Aaron SD, Webb KA, O’Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005;26:420-428.
Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality of COPD: role of comorbidities. Eur Respir J 2006;28:1245-1257.